Cargando…

The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life

BACKGROUND: Hunter syndrome (mucopolysaccharidosis type II (MPS II)) is a rare metabolic disease that can severely compromise health, well-being and life expectancy. Little evidence has been published on the impact of MPS II on health-related quality of life (HRQL). The objective of this study was t...

Descripción completa

Detalles Bibliográficos
Autores principales: Raluy-Callado, Mireia, Chen, Wen-Hung, Whiteman, David A H, Fang, Juanzhi, Wiklund, Ingela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722040/
https://www.ncbi.nlm.nih.gov/pubmed/23837440
http://dx.doi.org/10.1186/1750-1172-8-101
_version_ 1782278130791088128
author Raluy-Callado, Mireia
Chen, Wen-Hung
Whiteman, David A H
Fang, Juanzhi
Wiklund, Ingela
author_facet Raluy-Callado, Mireia
Chen, Wen-Hung
Whiteman, David A H
Fang, Juanzhi
Wiklund, Ingela
author_sort Raluy-Callado, Mireia
collection PubMed
description BACKGROUND: Hunter syndrome (mucopolysaccharidosis type II (MPS II)) is a rare metabolic disease that can severely compromise health, well-being and life expectancy. Little evidence has been published on the impact of MPS II on health-related quality of life (HRQL). The objective of this study was to describe this impact using the Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) questionnaire and a range of standard validated questionnaires previously used in paediatric populations. METHODS: Clinical and demographic characteristics collected in a clinical trial and responses to four HRQL questionnaires completed both by patients and parents prior to enzyme replacement treatment were used. The association between questionnaire scores and clinical function parameters were tested using Spearman rank-order correlations. Results were compared to scores in other paediatric populations with chronic conditions obtained through a targeted literature search of published studies. RESULTS: Overall, 96 male patients with MPS II and their parents were enrolled in the trial. All parents completed the questionnaires and 53 patients above 12 years old also completed the self-reported versions. Parents’ and patients’ responses were analysed separately and results were very similar. Dysfunction according to the HS-FOCUS and the CHAQ was most pronounced in the physical function domains. Very low scores were reported in the Self Esteem and Family Cohesion domains in the CHQ and HUI3 disutility values indicated a moderate impact. Scores reported by patients and their parents were consistently lower than scores in the other paediatric populations identified (except the parent-reported Behaviour score); and considerably lower than normative values. CONCLUSIONS: This study describes the impact on HRQL in patients with MPS II and provides a broader context by comparing it with that of other chronic paediatric diseases. Physical function and the ability to perform day-to-day activities were the most affected areas and a considerable impact on the psychological aspects of patients’ HRQL was also found, with a higher level of impairment across most dimensions (particularly Pain and Self Esteem) than that of other paediatric populations. Such humanistic data provide increasingly important support for establishing priorities for health care spending, and as a component of health economic analysis.
format Online
Article
Text
id pubmed-3722040
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37220402013-07-25 The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life Raluy-Callado, Mireia Chen, Wen-Hung Whiteman, David A H Fang, Juanzhi Wiklund, Ingela Orphanet J Rare Dis Research BACKGROUND: Hunter syndrome (mucopolysaccharidosis type II (MPS II)) is a rare metabolic disease that can severely compromise health, well-being and life expectancy. Little evidence has been published on the impact of MPS II on health-related quality of life (HRQL). The objective of this study was to describe this impact using the Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) questionnaire and a range of standard validated questionnaires previously used in paediatric populations. METHODS: Clinical and demographic characteristics collected in a clinical trial and responses to four HRQL questionnaires completed both by patients and parents prior to enzyme replacement treatment were used. The association between questionnaire scores and clinical function parameters were tested using Spearman rank-order correlations. Results were compared to scores in other paediatric populations with chronic conditions obtained through a targeted literature search of published studies. RESULTS: Overall, 96 male patients with MPS II and their parents were enrolled in the trial. All parents completed the questionnaires and 53 patients above 12 years old also completed the self-reported versions. Parents’ and patients’ responses were analysed separately and results were very similar. Dysfunction according to the HS-FOCUS and the CHAQ was most pronounced in the physical function domains. Very low scores were reported in the Self Esteem and Family Cohesion domains in the CHQ and HUI3 disutility values indicated a moderate impact. Scores reported by patients and their parents were consistently lower than scores in the other paediatric populations identified (except the parent-reported Behaviour score); and considerably lower than normative values. CONCLUSIONS: This study describes the impact on HRQL in patients with MPS II and provides a broader context by comparing it with that of other chronic paediatric diseases. Physical function and the ability to perform day-to-day activities were the most affected areas and a considerable impact on the psychological aspects of patients’ HRQL was also found, with a higher level of impairment across most dimensions (particularly Pain and Self Esteem) than that of other paediatric populations. Such humanistic data provide increasingly important support for establishing priorities for health care spending, and as a component of health economic analysis. BioMed Central 2013-07-10 /pmc/articles/PMC3722040/ /pubmed/23837440 http://dx.doi.org/10.1186/1750-1172-8-101 Text en Copyright © 2013 Raluy-Callado et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Raluy-Callado, Mireia
Chen, Wen-Hung
Whiteman, David A H
Fang, Juanzhi
Wiklund, Ingela
The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life
title The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life
title_full The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life
title_fullStr The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life
title_full_unstemmed The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life
title_short The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life
title_sort impact of hunter syndrome (mucopolysaccharidosis type ii) on health-related quality of life
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722040/
https://www.ncbi.nlm.nih.gov/pubmed/23837440
http://dx.doi.org/10.1186/1750-1172-8-101
work_keys_str_mv AT raluycalladomireia theimpactofhuntersyndromemucopolysaccharidosistypeiionhealthrelatedqualityoflife
AT chenwenhung theimpactofhuntersyndromemucopolysaccharidosistypeiionhealthrelatedqualityoflife
AT whitemandavidah theimpactofhuntersyndromemucopolysaccharidosistypeiionhealthrelatedqualityoflife
AT fangjuanzhi theimpactofhuntersyndromemucopolysaccharidosistypeiionhealthrelatedqualityoflife
AT wiklundingela theimpactofhuntersyndromemucopolysaccharidosistypeiionhealthrelatedqualityoflife
AT raluycalladomireia impactofhuntersyndromemucopolysaccharidosistypeiionhealthrelatedqualityoflife
AT chenwenhung impactofhuntersyndromemucopolysaccharidosistypeiionhealthrelatedqualityoflife
AT whitemandavidah impactofhuntersyndromemucopolysaccharidosistypeiionhealthrelatedqualityoflife
AT fangjuanzhi impactofhuntersyndromemucopolysaccharidosistypeiionhealthrelatedqualityoflife
AT wiklundingela impactofhuntersyndromemucopolysaccharidosistypeiionhealthrelatedqualityoflife